Mirum Pharmaceuticals
Commercializes rare-disease medicines while building a broader liver and genetic-disease pipeline.
$97.46
After-hours close0.00 (0.00%)
At close$97.46(−2.30%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 127.06%Insiders 1.74%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 60.98M · Float 52.46M · 86.0% free float
Institutions13F, as of Jun 30, 2026
337 holders · 77.48M shares · 64 new positions · 191 increased · 102 reduced · 45 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7.68M | 12.59% | 0 | Aug 14, 2026 |
| Jupiter Topco LLC | 5.91M | 9.69% | +5.91Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 4.39M | 7.20% | +543.5K | Aug 7, 2026 |
| FMR LLC | 3.67M | 6.02% | +1.70M | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 2.66M | 4.35% | +938.2K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 2.38M | 3.90% | +944.9K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 2.25M | 3.70% | −160.7K | Aug 13, 2026 |
| State Street Corp | 2.17M | 3.56% | +226.4K | Aug 7, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 14.30% | 22.74M | 13G | May 14, 2025 ↗ |
| Patrick J. Heronincl. Fhmls Xii, L.P., Frazier Life Sciences XII, L.P. +14 more | 6.80% | 4.11M | 13D | Jan 27, 2026 ↗ |
| BlackRock, Inc. | 5.70% | 3.47M | 13G | Apr 27, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Christopher Peetz | director, officer: CHIEF EXECUTIVE OFFICER | 381.8K | 0.63% | Aug 11, 2026 |
| Patrick J. Heron | director | 333.3K | 0.55% | Jan 27, 2026 |
| Michael G. Grey | director | 186.4K | 0.31% | Dec 23, 2025 |
| Peter Radovich | officer: PRESIDENT AND COO | 57.3K | 0.09% | Jun 8, 2026 |
| Eric Bjerkholt | officer: CHIEF FINANCIAL OFFICER | 36.4K | 0.06% | Aug 12, 2026 |
| Joanne Quan | officer: CHIEF MEDICAL OFFICER | 18.9K | 0.03% | Mar 17, 2026 |
| Laura Brege | director | 15.7K | 0.03% | Sep 12, 2025 |
| Laurent Fischer | director | 10.7K | 0.02% | Jun 2, 2026 |
| Lon Cardon | director | 9.7K | 0.02% | Jun 2, 2026 |
| Timothy P. Walbert | director | 9.7K | 0.02% | Jun 2, 2026 |
9 ten-percent owners hold 25.52M shares by Form 4, outside the officers-and-directors figure above · 6 people have not refiled in the last 18 months (3.37M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Jolanda Howeofficer: SVP, GLOBAL CONTROLLER | Sale | 40,000 | $100.00 | 1,274 |
| Aug 11, 2026 | Eric Bjerkholtofficer: CHIEF FINANCIAL OFFICER | Sale | 6,001 | $99.90 | 36,355 |
| Aug 10, 2026 | Christopher Peetzdirector, officer: CHIEF EXECUTIVE OFFICER | Sale · 3 lots | 20,000 | $98.92 | 194,309 |
| Aug 3, 2026 | Jolanda Howeofficer: SVP, GLOBAL CONTROLLER | Sale | 1,840 | $105.29 | 1,274 |
| Jul 6, 2026 | Eric Bjerkholtofficer: CHIEF FINANCIAL OFFICER | Sale · 4 lots | 5,000 | $122.25 | 42,181 |
| Jul 6, 2026 | Christopher Peetzdirector, officer: CHIEF EXECUTIVE OFFICER | Sale · 4 lots | 20,000 | $122.27 | 194,309 |
| Jul 1, 2026 | Jolanda Howeofficer: SVP, GLOBAL CONTROLLER | Sale | 2,721 | $120.00 | 3,114 |
| Jun 17, 2026 | Jolanda Howeofficer: SVP, GLOBAL CONTROLLER | Sale | 2,594 | $101.95 | 5,835 |
| Jun 8, 2026 | Eric Bjerkholtofficer: CHIEF FINANCIAL OFFICER | Sale · 3 lots | 5,000 | $93.82 | 44,788 |
| Jun 1, 2026 | Saira Ramasastrydirector | Sale | 3,977 | $100.00 | 0 |
CongressHouse and Senate disclosures
Not reported.